🇺🇸 kallikrein in United States

39 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Condition Aggravated — 6 reports (15.38%)
  2. Aplasia Pure Red Cell — 5 reports (12.82%)
  3. Decreased Appetite — 5 reports (12.82%)
  4. Pruritus — 4 reports (10.26%)
  5. White Blood Cell Count Decreased — 4 reports (10.26%)
  6. Blood Urea Increased — 3 reports (7.69%)
  7. Cerebral Infarction — 3 reports (7.69%)
  8. Diarrhoea — 3 reports (7.69%)
  9. Hepatic Function Abnormal — 3 reports (7.69%)
  10. Nausea — 3 reports (7.69%)

Source database →

Other Other approved in United States

Frequently asked questions

Is kallikrein approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for kallikrein in United States?

Techpool Bio-Pharma Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.